Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that compound 3 derived from aza-bicyclo-carboxylic acid may exert a cardioprotective effect by reducing infarction area in myocardial ischemia-reperfusion injury, potentially involving A1-adenosine receptor activation and changes in cAMP levels.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.

This article reviews the use of several medications for ovulation induction in polycystic ovary syndrome and hirsutism treatment, noting these uses are not FDA-approved; no new clinical results are provided.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study found that combining letrozole with metformin was more effective at inducing pregnancy in women with PCOS compared to letrozole alone, while OCP and metformin significantly improved menstrual regularity and reduced hyperandrogenic symptoms.

This study suggests that Dicer, but not Tarbp2, plays a crucial role in regulating the growth phase of hair follicles in bulge stem cells during post-natal development in mice.

In this study, all stereoisomers of cyoctol were synthesized and tested, revealing that contrary to initial patent claims, cyoctol does not function as an anti-androgen.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

This study found that supplementation with CL22209, a standardized Asparagus racemosus root extract, significantly reduced menopausal symptoms and improved hormonal regulation among early perimenopausal women, with notable improvements in vasomotor and menstrual symptoms compared to placebo, while being safe and well-tolerated over 120 days.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after 6 months compared to those containing levonorgestrel.

This study found that nanostructured lipid carriers with clobetasol propionate significantly enhance follicular drug delivery compared to commercial cream, and manual massage further doubles follicular retention.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This article reviews the complex nature and diagnostic criteria of polycystic ovary syndrome, and discusses its treatment options without reporting any new clinical results.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This article discusses the availability of data from TriNetX for research purposes and reports no new findings.